Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | TERT | O14746 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579717 | 0.90 | SMN1; SMN2 (0.52) | SMN1; SMN2TERTKDM4EPOLBCTDSP1 | |
| SCHEMBL1295 | 0.84 | SMN1; SMN2 (0.72) | SMN1; SMN2TERTKDM4EPOLBCTDSP1 | |
| SCHEMBL3586257 | 0.81 | TERT (0.43) | SMN1; SMN2TERTKDM4EPOLBKMT2A | |
| SCHEMBL1452 | 0.80 | SMN1; SMN2 (1.00) | SMN1; SMN2TERTL3MBTL1KMT2AMEN1 | |
| SCHEMBL331219 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2KDM4EPOLBCTDSP1TDP1 | |
| SCHEMBL28038421 | 0.79 | SMN1; SMN2 (0.60) | SMN1; SMN2KDM4EPOLBCTDSP1TDP1 | |
| SCHEMBL1527735 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2KDM4EPOLBCTDSP1TDP1 | |
| SCHEMBL3573728 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2TERTKDM4EPOLBCTDSP1 | |
| SCHEMBL6713099 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2TERTKDM4EPOLBKMT2A | |
| SCHEMBL6338203 | 0.76 | SMN1; SMN2 (0.60) | SMN1; SMN2TERTPOLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060293347-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | PFIZER INC | 2006-12-28 | — | — | US | disclosed |
| EP-1220856-B1 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES | PFIZER LTD (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20040152712-A1 | Pharmaceutically active compounds | PFIZER INC. | 2004-08-05 | — | — | US | disclosed |
| US-6677335-B1 | PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE DERIVATIVES; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; SEXUAL AND UROGENITAL DISORDERS | PFIZER INC | 2004-01-13 | — | — | US | disclosed |
| EP-1220856-A2 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES | Pfizer Limited (GB) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001027113-A2 | PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035891-A1 | Pharmaceutically Active Compounds | PDE5A, PDE3A, PDE3B | SMN1; SMN2 1628/4885TERT 4584/4885KDM4E 1883/4885 |
| US-20060293347-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | PDE5A, PDE3A, PDE3B | SMN1; SMN2 1628/4885TERT 4584/4885KDM4E 1883/4885 |
| US-20040152712-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | SMN1; SMN2 1627/4885TERT 4292/4885KDM4E 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.